Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety
European Journal of Clinical Microbiology & Infectious Diseases · 2025
DOI: 10.1007/s10096-024-04921-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Bart Forier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Leuven Transplant Center and Department of Respiratory Diseases, University Hospitals Leuven, Herestraat 49, Leuven, B-3000, Belgium. Hauptthemen laut MEDLINE: Lung Transplantation, Anti-Bacterial Agents, Ambulatory Care, Bacterial Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Research Fund, University Hospitals Leuven, Belgium, Fonds Wetenschappelijk Onderzoek, Emilie van Heel Foundation.
Abstract (Originalsprache)
PURPOSE: Bacterial isolation is associated with worse outcomes after lung transplantation (LTx), and successful bacterial eradication is shown to improve long-term survival and pulmonary function. Outpatient Parenteral Antibiotic Therapy (OPAT) may be an effective therapeutic modality for bacterial eradication post-LTx. METHODS: A single-center, retrospective analysis of OPAT characteristics, efficacy, safety, and costs in non-cystic fibrosis LTx recipients. RESULTS: A total of 156 OPAT courses (from June 2019 to December 2022) were evaluated in 108 distinct LTx recipients. OPAT mainly consisted of dual antibiotic therapy (69%) for pulmonary bacterial isolation (97%), mostly Pseudomonas aeruginosa (66%). Successful eradication at 3 months post-OPAT was achieved in 71%. Eradication rate was significantly higher in patients treated after the first post-operative year (79%), compared to patients within the first year (61%) (p = 0.017). Eradication rate was similar for multidrug resistance (eradication rate 61%) versus no multidrug resistance (74%) (p = 0.116). Spirometry remained stable at 90 days post-OPAT. A statistically significant, but clinically negligible, increase in serum creatinine at 90 days post-OPAT was observed (1.33 mg/dL vs. 1.39 mg/dL, p < 0.001), yet unrelated to the antibiotic regimen used. OPAT-related hospital admissions occurred in 13% and line-related adverse events in 6%. Median number of hospitalization days saved per OPAT-course was 10 days (range 2-92), accounting for a total of 1841 avoided admission days and an estimated net cost reduction of 47% per treatment course. CONCLUSION: OPAT is an effective and safe therapeutic modality for bacterial eradication post-LTx, associated with a significant reduction in hospitalization days and treatment costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leuven Transplant Center and Department of Respiratory Diseases, University Hospitals Leuven, Herestraat 49, Leuven, B-3000, Belgium.
- Lung Transplant Team, Clinical Nurse Specialist, University Hospitals Leuven, Leuven, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
- Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium.
Förderung
- Clinical Research Fund, University Hospitals Leuven, Belgium
- Fonds Wetenschappelijk Onderzoek
- Emilie van Heel Foundation
Zitieren
APA
Forier, B., Schaevers, V., Spriet, I., Quintens, C., Desmet, S., Bos, S., Bleyenbergh, P. V., Lorent, N., Sadeleer, L., Godinas, L., Dupont, L. J., & Vos, R. (2025). Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04921-9
Vancouver
Forier B, Schaevers V, Spriet I, Quintens C, Desmet S, Bos S, et al. Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-024-04921-9
BibTeX
@article{Forier2025,
author = {Forier, Bart and Schaevers, Veronique and Spriet, Isabel and Quintens, Charlotte and Desmet, Stefanie and Bos, Saskia and Bleyenbergh, Pascal Van and Lorent, Natalie and Sadeleer, Laurens De and Godinas, Laurent and Dupont, Lieven J and Vos, Robin},
title = {Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2025},
doi = {10.1007/s10096-024-04921-9}
}
EUVIMED